Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsMax Lataillade, MPH, DO
Assistant Clinical ProfessorAbout
Research
Publications
2025
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study
Joshi S, Masiá M, Mitha E, Castagna A, Cordova E, Ramgopal M, Gaudion A, Karthika S, Oyee J, Bainbridge V, Wynne B, Lataillade M. Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study. EClinicalMedicine 2025, 89: 103566. PMID: 41357331, PMCID: PMC12675015, DOI: 10.1016/j.eclinm.2025.103566.Peer-Reviewed Original ResearchNaive to antiretroviral therapyPhase 2b studyHIV-1 RNAAntiretroviral therapyHIV-1Intention-to-treat-exposed populationProtocol-defined virologic failureDouble-blind doseTwo-drug regimenHIV-1 treatmentVirological failureAntiretroviral regimensFatal AEDouble-blindPrimary endpointMechanism of actionStudy treatmentProportion of participantsDolutegravirMaturation inhibitorsTherapyEligible participantsEfficacyWeeksDoseEfficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study
Joshi S, Cordova E, Mitha E, Castagna A, Ramgopal M, Llibre J, Potthoff A, Chernova O, Nuñez S, Man C, Jeffrey J, Fishman C, Oyee J, Joshi A, Zhang Y, Bainbridge V, Wynne B, Lataillade M. Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study. EClinicalMedicine 2025, 89: 103567. PMID: 41357330, PMCID: PMC12675029, DOI: 10.1016/j.eclinm.2025.103567.Peer-Reviewed Original ResearchNucleoside reverse transcriptase inhibitorsNaive to antiretroviral therapyHIV-1 RNAAntiretroviral therapyHIV-1Intention-to-treat-exposed populationProtocol-defined virologic failureDouble-blind doseTreatment-emergent resistancePhase 2b trialPhase 2b studyReverse transcriptase inhibitorsDolutegravir groupVirological failurePrimary endpointMechanism of actionTranscriptase inhibitorsMaturation inhibitorsDolutegravirTherapyEligible participantsEfficacyWeeksTrialsDose
2023
Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants
Zhang Y, Bush M, Yazdani P, Zhan J, Wen B, Bainbridge V, Wynne B, Joshi S, Lataillade M. Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants. Pharmacology Research & Perspectives 2023, 11: e01151. PMID: 37961928, PMCID: PMC10644204, DOI: 10.1002/prp2.1151.Peer-Reviewed Original ResearchConceptsConcentration-QTc analysisHealthy participantsQT intervalNovel HIV-1 maturation inhibitorsPlacebo-adjusted changeHIV-1 treatmentHIV-1 maturation inhibitorsMoxifloxacin doseSupratherapeutic dosePlasma concentrationsRelevant effectsFridericia's formulaTreatment periodCardiac repolarizationHeart rateMaturation inhibitorsCardiac conductionCardiac parametersDay 7QT studyDoseTime pointsGSK3640254ΔΔQTcFPharmacokinetics